U S Food and Drug Administration Home Page

- FDA releases Biosimilars Action Plan
- Plan outlines key FDA actions to encourage innovation and competition among biologics and the development of biosimilars
- FDA releases Biosimilars Action Plan
- FDA approves first drug containing cannabidiol
- Approval exemplifies importance of proper research to prove safe, effective medical uses for active chemicals in marijuana
- FDA approves first drug containing cannabidiol
- OTC benzocaine teething products pose serious risk
- FDA takes action to discontinue these products, add warnings to other OTC oral health products containing benzocaine
- OTC benzocaine teething products pose serious risk

Newsroom Meetings Testimonies Speeches

Newsroom

For Consumers
Updates and information for staying safe and healthy
For Patients
Learn about other treatments, drug/device approvals, public meetings and more
For Health Professionals
Medical product safety information, adverse event/problem reporting and more
For Scientists & Researchers
NCTR, pediatrics, clinical trials, Critical Path Initiative, foods and veterinary medicine research, and more
For Industry
Guidance, registration and listing, pay user fees, import programs and more

FDA releases Biosimilars Action Plan